TECH
Bio-Techne Corporation · Healthcare
Insiders sold $437K of Bio-Techne Corporation in the last 12 months and bought none
TECH over the last year
TECH after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Congress
Members reported 31 trades in TECH since 2023.
Every filing
96 insider filings since 2016, newest first
Amy E. Herr · Director
Amy E. Herr · Director
Robert Baumgartner V · Director
John L Higgins · Director
Roeland Nusse · Director
Roeland Nusse · Director
Charles R. Kummeth · CEO
Charles R. Kummeth · CEO
Brenda S. Furlow · SVP - GC
John L Higgins · Director
John L Higgins · Director
Charles R. Kummeth · CEO
Robert Baumgartner V · Director
Kim Kelderman · Pres Diagnostics, Genom
Norman David Eansor · Pres-Protein Sciences
James Hippel · CFO
James Hippel · CFO
Kim Kelderman · Pres Diagnostics, Genom
Randolph C Steer · Director
James Hippel · CFO
Brenda S. Furlow · SVP - GC
Norman David Eansor · Pres-Protein Sciences
Brenda S. Furlow · SVP - GC
Roeland Nusse · Director
Robert Baumgartner V · Director
Brenda S. Furlow · SVP - GC
James Hippel · CFO
James Hippel · CFO
Charles R. Kummeth · CEO
Charles R. Kummeth · CEO
Kim Kelderman · Pres Diagnostics, Genom
James Hippel · CFO
Kim Kelderman · Pres Diagnostics, Genom
James Hippel · CFO
Brenda S. Furlow · SVP - GC
Roeland Nusse · Director
Kim Kelderman · Pres Diagnostics, Genom
Norman David Eansor · Pres-Protein Sciences
Charles R. Kummeth · CEO
James Hippel · CFO
Charles R. Kummeth · CEO
Brenda S. Furlow · SVP - GC
Robert Baumgartner V · Director
Alpna Seth · Director
James Hippel · CFO
Randolph C Steer · Director
John L Higgins · Director
James Hippel · CFO
Brenda S. Furlow · SVP - GC
James Hippel · CFO
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.